{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:13:40Z","timestamp":1794093220001,"version":"4.8.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013956","name":"Dutch Research Council Domain Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["KWF #10174"],"award-info":[{"award-number":["KWF #10174"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["11809"],"award-info":[{"award-number":["11809"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["19027"],"award-info":[{"award-number":["19027"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand up to Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT1415"],"award-info":[{"award-number":["SU2C-AACR-DT1415"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA233259"],"award-info":[{"award-number":["CA233259"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA121113"],"award-info":[{"award-number":["CA121113"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004436","name":"Commonwealth Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.esmoop.2025.105935","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T13:26:37Z","timestamp":1767360397000},"page":"105935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Added value of tumor\u2013stroma ratio to postsurgery circulating tumor DNA and pTN stage in risk stratification of patients with stage III colon cancer treated with adjuvant chemotherapy"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-6545","authenticated-orcid":false,"given":"I.A.","family":"Franken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9918-575X","authenticated-orcid":false,"given":"F.","family":"Heilijgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2072-9096","authenticated-orcid":false,"given":"M.-C.E.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rubio-Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-6547","authenticated-orcid":false,"given":"F.H.","family":"van der Baan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lemmens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Delis-van","family":"Diemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-5269","authenticated-orcid":false,"given":"M.","family":"Sausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0330-3130","authenticated-orcid":false,"given":"G.A.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6731-9660","authenticated-orcid":false,"given":"G.R.","family":"Vink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.A.","family":"Fijneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5533-4778","authenticated-orcid":false,"given":"W.E.","family":"Mesker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.L.","family":"Roodhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.esmoop.2025.105935_bib1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105935_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114207","article-title":"Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months","volume":"208","author":"Franken","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105935_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.07.031","article-title":"A new prognostic and predictive tool for shared decision making in stage III colon cancer","volume":"138","author":"Sobrero","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105935_bib4","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.2017.76.0355","article-title":"Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial","volume":"36","author":"Andr\u00e9","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105935_bib5","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2025.105935_bib6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2022.04.010","article-title":"Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: a prospective cohort study","volume":"169","author":"Li","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105935_bib7","article-title":"Circulating tumour DNA (ctDNA) in patients with stage III colon cancer: the multicentre prospective PROVENC3 study","author":"Franken","year":"2025","journal-title":"Br J Surg"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105935_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","article-title":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","volume":"28","author":"Henriksen","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105935_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105935_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41571-023-00834-2","article-title":"Personalizing adjuvant therapy for patients with colorectal cancer","volume":"21","author":"Yang","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105935_bib11","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1200\/JCO-25-00205","article-title":"Entering the era of multidimensional prognostication for personalized risk assessment in stage III colon cancer","volume":"43","author":"Rousseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105935_bib12","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/jnci\/djs427","article-title":"Integrated analysis of molecular and clinical prognostic factors in stage II\/III colon cancer","volume":"104","author":"Roth","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105935_bib13","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105935_bib14","first-page":"169","article-title":"Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients","volume":"31","author":"Mesker","year":"2009","journal-title":"Cell Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105935_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1155\/2007\/175276","article-title":"The carcinoma\u2013stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage","volume":"29","author":"Mesker","year":"2007","journal-title":"Anal Cell Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105935_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/his.13489","article-title":"The tumour\u2013stroma ratio in colon cancer: the biological role and its prognostic impact","volume":"73","author":"van Pelt","year":"2018","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105935_bib17","doi-asserted-by":"crossref","DOI":"10.2196\/13464","article-title":"Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: protocol for a multicenter prospective cohort study","volume":"8","author":"Smit","year":"2019","journal-title":"JMIR Res Protoc"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105935_bib18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00428-018-2408-z","article-title":"Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations","volume":"473","author":"van Pelt","year":"2018","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105935_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102988","article-title":"Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor\u2013stroma ratio in colon cancer","volume":"9","author":"Polack","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105935_bib20","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/0284186X.2016.1189094","article-title":"Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research","volume":"55","author":"Burbach","year":"2016","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105935_bib21","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2025.105935_bib22","first-page":"19","article-title":"Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105935_bib23","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1158\/1078-0432.CCR-24-1651","article-title":"Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay","volume":"30","author":"Nakamura","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105935_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","article-title":"Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer\u2014evaluation in a nationwide Danish cohort","volume":"35","author":"Henriksen","year":"2024","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105935_bib25","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1200\/JCO.23.02262","article-title":"Prognostic models from transcriptomic Signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA-France trials","volume":"43","author":"Gallois","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105935_bib26","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-24-3200","article-title":"Timing of ctDNA analysis aimed at guiding adjuvant treatment in colorectal cancer","volume":"31","author":"Henriksen","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105935_bib27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/cjp2.207","article-title":"Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid","volume":"7","author":"van\u2019t Erve","year":"2021","journal-title":"J Pathol Clin Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105935_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1245\/s10434-022-12399-y","article-title":"Circulating tumor DNA is unreliable to detect somatic gene alterations in gastrointestinal peritoneal carcinomatosis","volume":"30","author":"Sullivan","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105935_bib29","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.24.00648","article-title":"Combined analyses of circulating tumor DNA and immunoscore in patients with stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France\/HORG-IDEA-Greece Trials","volume":"43","author":"Taieb","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105935_bib30","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2025.43.16_suppl.3504","article-title":"Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147)","volume":"43","author":"Sinicrope","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105935_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100738","article-title":"Prognostic value of tumor-stroma ratio in a screened stage II colon cancer population: intratumoral site-specific assessment and tumor budding synergy","volume":"38","author":"Kristensen","year":"2025","journal-title":"Mod Pathol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105935_bib33","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105935_bib34","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jamaoncol.2019.2572","article-title":"Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial","volume":"5","author":"Yoshino","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105935_bib35","article-title":"A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients (Pts): the SAGITTARIUS trial","volume":"43","author":"Montagut","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105935_bib36","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2025.43.16_suppl.3503","article-title":"ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: primary analysis of the CtDNA-positive cohort from the randomized AGITG dynamic-III trial (intergroup study of AGITG and CCTG)","volume":"43","author":"Tie","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2025.105935_bib37","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1538-7445.AM2024-2496","article-title":"Abstract 2496: Molecular characterization of stage III colon cancer patients with recurrence after adjuvant chemotherapy","volume":"84","author":"Franken","year":"2024","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105935_bib38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105935_bib39","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","article-title":"Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial","volume":"23","author":"Yamazaki","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105935_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf069","article-title":"A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations","volume":"30","author":"Wheless","year":"2025","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105935_bib41","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4161\/cbt.6.11.4874","article-title":"Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer","volume":"6","author":"Narra","year":"2007","journal-title":"Cancer Biol Ther"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925018058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:55:42Z","timestamp":1773960942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925018058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2059702925018058"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105935","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Added value of tumor\u2013stroma ratio to postsurgery circulating tumor DNA and pTN stage in risk stratification of patients with stage III colon cancer treated with adjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105935"}}